Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Fig. 2

Primary efficacy outcome analysis: change from baseline to week 78. a ADAS-Cog/11: total score range is 0 (least impairment) to 70 (most impairment). A positive change from baseline indicates worsening cognitive impairment. b DAD: total score range is 0 to 100, with higher scores indicating better function. A negative change from baseline indicates worsening function. Data shown are least squares means with standard error of the mean. ADAS-Cog/11, 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale; ApoE, apolipoprotein E; BAP, bapineuzumab; DAD, Disability Assessment for Dementia; LS, least squares

Back to article page